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Abstract
Objective—To examine the association between changes in waist-hip ratio (WHR), a measure of 
abdominal obesity, and age-related macular degeneration (AMD).
Methods—A total of 12 515 persons from a population-based cohort study, aged 45 to 64 years 
in 1987 to 1989, were followed up over 6 years. The percentage change in WHR during follow-up 
was ranked into sex-specific deciles; an increase in WHR was defined as the top 10% of change 
and a decrease in WHR as the bottom 10%. The association of increased or decreased WHR and 
presence of AMD at follow-up was determined using logistic regression adjusting for potential 
confounders.
Results—The average change in WHR was an increase of 2%, ranging from a decrease of 44% 
to an increase of 102%. A decrease in WHR of 3% or more was associated with 29% lower odds 
of any AMD (odds ratio = 0.71; 95% confidence interval, 0.52–0.97). This effect was most 
pronounced among obese participants at baseline, where a decrease in WHR was associated with 
59% lower odds of AMD (odds ratio = 0.41; 95% confidence interval, 0.20–0.82).
Conclusions—Middle-aged persons who had a 3% or greater reduction in WHR over time were 
less likely to have AMD, particularly among those who were initially obese.
Age-related macular degeneration (AMD) is the leading cause of visual impairment among 
elderly persons. Despite advances in research, few modifiable risk factors for AMD have 
been identified. Although clear associations have been shown with smoking, associations 
Correspondence: Tien Y. Wong, MD, PhD, Centre for Eye Research Australia, University of Melbourne, 32 Gisborne St, East 
Melbourne 3002, Australia (twong@unimelb.edu.au). 
Financial Disclosure: None reported.
HHS Public Access
Author manuscript
Arch Ophthalmol. Author manuscript; available in PMC 2018 January 19.
Published in final edited form as:













with hypertension, cardiovascular disease, dyslipidemia, and dietary fat intake have not been 
consistent.1–4
The relationship between obesity and AMD has been the subject of several studies (Table 1), 
including cross-sectional and case-control studies5–7,15 and more recently longitudinal 
studies.8,9,11,12,14 Most of these have examined AMD associations with overweight and 
obesity defined by the body mass index (BMI) (calculated as weight in kilograms divided by 
height in meters squared).5,11 Some studies investigating the relationship between BMI and 
incident AMD have found no association9,13,16 or have found associations solely within 
specific population subgroups such as women.10
The waist-hip ratio (WHR) is a measure of central or abdominal obesity. There is now 
increasing evidence that WHR is a better predictor of diabetes and cardiovascular diseases 
than BMI.17 However, only 2 studies have investigated relationships between WHR and 
AMD,10,12 with one of them showing stronger relationships between WHR and AMD than 
between BMI and AMD.
To our knowledge, there has been no analysis of the association between changes in WHR, 
BMI, or weight with the presence of AMD to date. In the current study, we use longitudinal 
data from the Atherosclerosis Risk in Communities Study to examine the relationship 
between changes in WHR during a 6-year period and presence of AMD at the end of the 6-
year period. Our hypothesis is that WHR, a measure of central obesity, and changes in WHR 
over time are associated with the prevalence of AMD.
METHODS
STUDY POPULATION
The Atherosclerosis Risk in Communities Study is a population-based cohort study that 
included 15 792 women and men aged 45 to 64 years at baseline in 1987 to 1989.18 
Population samples were selected from 4 US communities. Of those examined at baseline, 
86% of the survivors returned for the third examination 6 years after the baseline 
examination (1993–1995).
Our study population comprised persons who returned to the third examination, when retinal 
photography was first performed.4,19,20 Of the 12 887 who returned for this examination, we 
excluded 271 with no retinal photographs or with ungradable photographs, 30 without 
measurements of weight, height, waist circumference, or hip circumference, and, owing to 
small numbers, 38 whose race was neither black nor white and 42 black residents in 
Minneapolis, Minnesota, and Maryland, leaving 12 506 who provided data for this study. 
Characteristics of participants with and without gradable retinal photographs have been 
previously reported.19
Institutional review boards at each study site and at the Fundus Photograph Reading Center, 
University of Wisconsin, Madison, approved the study. Informed consent was obtained from 
all of the participants, and the study was conducted in accordance with the Declaration of 
Helsinki.
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WHR, BMI, AND WAIST CIRCUMFERENCE
Waist and hip circumferences were determined by horizontal measurement of the maximum 
girth at the umbilicus and over the buttocks, respectively.
To analyze the relationship between change in WHR from baseline and the third 
examination and AMD at the third examination, we defined change in 2 ways: absolute and 
relative. Absolute change (in centimeters) was defined as the difference between WHR at 
baseline and WHR at the third examination. Relative change was defined as the percentage 
change in WHR between baseline and the third examination. For categorical comparisons, 
we wanted categories of decreased and increased WHR to contain a change of at least 3% 
based on current ideas of clinical significance.21 We divided change in WHR into sex-
specific deciles; decreased WHR was defined for primary analyses as the bottom decile of 
percentage change (including change of −3% to −44%), increased WHR was defined as the 
top decile of percentage change (including change of 6% to 102%), and stable WHR was 
defined as the intermediate 8 deciles. Change in waist circumference was similarly defined.
Height and weight circumferences were measured with participants in scrub suits. For 
analysis by weight group, the population was divided into normal weight (BMI ≥18.5 and 
<25), overweight (BMI ≥25 and <30), and obese (BMI ≥30) groups.22 Owing to their small 
numbers (88 individuals), those with BMI less than 18.5 were not included in the analyses 
stratified by weight group. We defined changes in BMI in the same way as WHR.
RETINAL PHOTOGRAPHY AND AGE-RELATED MACULAR DEGENERATION
The retinal photography procedure and the assessment of AMD have been previously 
reported.4,20,23 Briefly, a 45° nonmydriatic retinal photograph centered on the region of the 
optic disc and the macula of 1 randomly selected eye of each participant was taken following 
5 minutes of dark adaptation. Graders masked to subject identity evaluated the photographs 
at the University of Wisconsin, Madison, using a modification of the Wisconsin AMD 
grading system.24 The presence of soft drusen, retinal pigment epithelial depigmentation, 
increased retinal pigment, pure geographic atrophy, and signs of exudative macular 
degeneration were determined in the macular area circumscribed by the outermost circle of 
the grading grid.
Soft drusen were defined as those having a diameter larger than 63 µm. Retinal pigment 
epithelial depigmentation and increased retinal pigment associated with AMD (the presence 
of granules or clumps of gray or black pigment in or beneath the retina) were defined as 
present or absent/questionable. Early AMD was defined as the presence of soft drusen alone, 
retinal pigment epithelial depigmentation alone, or a combination of soft drusen with 
increased retinal pigment and/or retinal pigment epithelial depigmentation in the absence of 
late AMD. Late AMD was defined as the presence of signs of exudative AMD or pure 
geographic atrophy. Any AMD was defined as the presence of either early or late AMD.
Quality-control procedures were based on repeated assessment of photographs for 520 
participants.19 In general, weighted κ of signs of AMD ranged from 0.67 to 0.81 for 
intragrader comparisons and 0.55 to 0.92 for intergrader comparisons.
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Participants were evaluated for cardiovascular risk factors at each examination.25 Patients 
were defined as having preexisting coronary heart disease if they had a history of acute 
myocardial infarction, silent infarction, or coronary revascularization procedures at baseline. 
Blood pressure was taken according to a standardized protocol with a random-zero 
sphygmomanometer, and the mean of the last 2 measurements was used.25 Blood was drawn 
after the patient had fasted overnight and processing was performed for total cholesterol, 
low-density lipoprotein cholesterol, triglycerides, glucose, and fibrinogen levels and white 
blood cell count as described elsewhere.25,26 Diabetes mellitus was defined as a fasting 
glucose level of 126 mg/dL or higher (to convert to millimoles per liter, multiply by 0.0555), 
a nonfasting glucose level of 200 mg/dL or higher, or a self-reported history of or treatment 
for diabetes. Education and cigarette smoking were ascertained from interview. Education 
was divided into basic (<12 years), intermediate (12–16 years), or advanced (17–21 years) 
levels. Participants were categorized as current, former, and never smokers, and years of 
smoking cigarettes were also recorded. Physical activity was characterized by sports and 
leisure activity indexes (scores within each index ranging from 0–5) described elsewhere.
27,28
STATISTICAL ANALYSES
The crude distribution of potential confounders across categories of change in WHR was 
determined by analysis of variance. To analyze the cross-sectional relationship between 
WHR and AMD, logistic regression was performed on AMD at examination 3 using 
standardized values of WHR measured at examination 3 and confounders measured at 
examination 3. All of the analyses were adjusted for sex, age (continuously), race, and study 
center. A second set of models was additionally adjusted for smoking status, blood glucose 
level, systolic blood pressure, serum total cholesterol level, the presence of coronary heart 
disease or diabetes, physical activity level, fibrinogen level, and white blood cell count 
measured at baseline.
To analyze the relationship between change in WHR, BMI, or waist circumference between 
baseline and the third examination and AMD at the third examination, we used sex-specific 
deciles of relative change as described earlier. The association between change in weight and 
AMD was analyzed using logistic regression with the stable weight group (deciles 2–9) as 
the reference group and presence or absence of AMD at the third examination as the 
outcome.
All of the analyses were adjusted for sex, age, race, and study center. A second set of models 
was additionally adjusted for baseline WHR, BMI, or waist circumference in the analyses of 
change in WHR, BMI, or waist circumference, respectively. A third set of models was also 
adjusted for baseline BMI or WHR, smoking status, years of cigarette smoking, change in 
smoking status during follow-up, serum glucose level, systolic blood pressure, serum total 
cholesterol level, the presence of coronary heart disease or diabetes, physical activity level, 
fibrinogen level, and white blood cell count, all measured at baseline. If one of the variables 
was used for stratification, it was no longer included in the model. Subgroup analyses were 
performed after stratifying by sex, age group, weight group, diabetes status, smoking status, 
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and race. Interaction terms for each of the stratification variables with change in WHR were 
also tested in the logistic regression models. All of the analyses were performed using 
Stata/SE version 8.0 statistical software (Stata Corp, College Station, Texas).
RESULTS
Between baseline and the third examination, the average change in WHR was an increase of 
1% for men and 3% for women, ranging from a decrease of 44% to an increase of just more 
than 100% (Figure). Those whose WHRs decreased, increased, or remained stable differed 
according to race, education, baseline WHR, obesity prevalence, baseline coronary heart 
disease, diabetes prevalence, and baseline cardiovascular disease risk factors (Table 2). In 
general, the group with decreasing WHR had the highest baseline levels of cardiovascular 
risk factors, including BMI and WHR.
There was a positive cross-sectional relationship between WHR at examination 3 and 
presence of AMD at examination 3 (Table 3). After full multivariate adjustment, the 
increased odds of any AMD associated with a 1-SD increase in WHR was 14% (95% 
confidence interval [CI], 1.02–1.27). An association was seen with all forms of AMD 
analyzed. There was no association between BMI at examination 3 and presence of AMD 
(odds ratio [OR] = 1.02 per 1-SD increase; 95% CI, 0.92–1.12).
There was a slight increase in the prevalence of AMD across the WHR relative change 
categories, with 50 cases of AMD (4%) in the group with decreasing WHR, 495 cases (5%) 
in the group with stable WHR, and 63 cases (5%) in the group with increasing WHR. There 
was no significant association between continuous change in WHR (OR = 1.09 per 1-SD 
change; 95% CI, 0.99–1.19) and the presence of AMD after full multivariate adjustment.
Having a decrease in WHR was associated with 29% lower odds of any AMD in the total 
population (Table 4). Such a decrease was associated with lower odds of early AMD and 
soft drusen but not with retinal pigment epithelial pigmentary abnormalities. We were 
unable to analyze late AMD as there were no cases within the decrease group and only 4 
within the increase group. No factors for which the variables were adjusted appreciably 
altered the associations observed (Table 4).
Among persons who were obese at baseline, a decrease in WHR was associated with 59% 
lower odds of AMD (OR = 0.41; 95% CI, 0.20–0.82) (Table 5). There was no relationship 
between a decrease in WHR and a decreased risk of AMD in those who were overweight or 
normal weight at baseline. However, there was no significant interaction between WHR 
change category and baseline weight group (P =.23). No factors for which the variables were 
adjusted appreciably altered the associations observed (Table 5).
There was no large significant relationship between an increase in WHR over time and 
increased odds of AMD (Table 4). Stratification by weight category suggested that an 
increase in WHR was associated with increased odds of any AMD in individuals with 
normal weight (Table 5), although this was not statistically significant in the fully adjusted 
model (P = .09).
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Analyses were also performed in subgroups defined by sex, diabetes, race, and smoking 
status. A decrease in WHR was significantly associated with lower odds of having AMD 
compared with those with stable WHR in women (OR = 0.63;95%CI, 0.40–0.98) and 
nonsmokers (OR = 0.60; 95% CI, 0.46–0.93). However, no interaction terms between 
change in WHR, so defined, and sex, diabetes, race, or smoking status were found to be 
significant.
When categories were defined by absolute change in WHR, the same trends seen earlier 
were observed (data not shown). After adjustment for age, sex, race, and center, a decrease 
in WHR was associated with decreased odds of AMD in the total population (OR = 0.74; 
95% CI, 0.55–1.00). In the obese subpopulation, the fully adjusted OR for AMD was 0.59 
(95% CI, 0.33–1.06).
Analysis of the relationship of percentage change in BMI with AMD demonstrated a 
relationship similar to that with WHR (data not shown), although the relationship with a 
large decrease in weight was generally weaker. There was no relationship between decreases 
in BMI and AMD in the total population (OR = 0.99; 95% CI, 0.74–1.32). In the obese 
subpopulation, there were decreased odds of 50% (95% CI, 0.27–0.89). A similar 
relationship with change in waist circumference, similarly defined, was also observed (data 
not shown), although the only significant association was that between a decrease in waist 
circumference and AMD in the obese subpopulation (OR = 0.34; 95% CI, 0.16–0.71).
COMMENT
In this middle-aged population, a decrease in WHR over a 6-year period, defined as the 
bottom decile of percentage change in WHR, was associated with a reduced prevalence of 
AMD. This effect was particularly apparent among persons who were obese at baseline, 
with a 61% decrease in the odds of AMD associated with a reduction in WHR over time. 
While there was a trend to suggest that increases in WHR were also associated with an 
increased prevalence of AMD, this relationship was not statistically significant.
Our findings suggest a role of weight loss in preventing the development of AMD, adding to 
existing literature on the increased risk of AMD associated with higher BMI and WHR 
(Table 1). Prospective data from the Physicians’ Health Study, for example, demonstrated 
that the 15-year incidence for visually significant dry AMD was highest in obese men and 
lowest in men with normal BMI while controlling for age and smoking.11 The mechanisms 
linking higher body weight with AMD are still unclear. Prior studies have suggested that 
oxidative stress may be one such mechanism.29–31 Other risk factors for AMD, including 
physical inactivity,32 hypertension, and hyperlipidemia, are also associated with obesity, 
suggesting that these associations may reflect shared risk factors. However, associations 
between WHR and AMD were independent of these risk factors.
Our finding of a reduction in WHR related to decreased odds of prevalent AMD is consistent 
with studies showing that weight loss leads to improvements in cardiovascular risk factors, 
including diabetes and hypertension.33–36 Studies have further suggested that the beneficial 
effects of weight loss are most apparent among the overweight or obese,34,35 which supports 
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the stronger association we found for AMD in persons who were obese. One problem with 
analyzing observational weight loss data is that unintentional weight loss is often caused by 
illness, leading to an association between weight loss and ill health or mortality. Studies 
specifically analyzing intentional weight loss have generally found it to be beneficial for 
health.35 In our study, we did not have data to differentiate intentional weight loss, so it is 
possible that the true beneficial effects observed are underestimated. However, including 
only individuals free of coronary heart disease and diabetes at baseline had little effect on 
the results.
The finding that weight gain (both absolute and relative changes) was not significantly 
associated with an increased risk of AMD was somewhat unexpected. There was a 
suggestion of increased AMD risk among persons with normal weight at baseline. This was 
also seen in another study where substantial weight gain was significantly associated with 
increased cardiovascular risk only in younger men with normal weight.34
Three observations deserve comment. First, the relationship with AMD was stronger when 
weight loss was defined according to WHR rather than BMI. Waist-hip ratio is now 
considered a better measure of abdominal obesity and thus cardiovascular risk.17 Second, 
there is evidence that relative weight change is a better indicator of metabolic risk than 
absolute change.21 While we found the same trends when comparing absolute and relative 
WHR changes, only the relationships with relative change were statistically significant. 
Third, because the relationships were not continuous, weight change was analyzed 
categorically. We defined increases and decreases in weight as the sex-specific top and 
bottom deciles of percentage weight change (as the most extreme changes present in 
sufficient numbers to provide adequate power) vs the intermediate 8 deciles as the reference 
group. The percentage changes contained within these deciles were 3% to 44% loss and 6% 
to 102% gain in WHR. In a recent article, Stevens et al21 suggested that weight maintenance 
be defined as a change of less than 3% of body weight. Within the 6-year follow-up in this 
study, approximately one-third of participants increased their WHR by 3% or more. 
Nevertheless, a repeated analysis using a ±3% cutoff for WHR change showed no significant 
associations. It will be important to repeat these findings in other studies as the extremes of 
weight change examined here may not be applicable to other populations.
The primary limitation of this study is that we were restricted to measuring the occurrence 
rather than incidence of AMD. Thus, we cannot conclude on the causative nature of 
improvements in WHR with lower risk of AMD. Additional studies analyzing the effect of 
improvements in WHR and the incidence of AMD are thus necessary. A second limitation is 
that retinal photography was performed in only 1 eye for each participant. Consequently, the 
AMD prevalence we found may be lower than the true prevalence, weakening observed 
effects. A third limitation is that uncontrolled confounding remains a possible explanation of 
the observed relationships. Finally, in this middle-aged population, there were insufficient 
numbers to analyze late AMD.
In conclusion, we show that a reduction in WHR in middle-aged persons, particularly those 
who were initially obese, may be associated with a decrease in the likelihood of prevalent 
AMD. With increasing prevalence of obesity, these results should be confirmed in future 
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studies as reduction in risk of AMD may be an additional benefit of reducing weight, 
especially in obese and overweight patients.
Acknowledgments
Funding/Support: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study 
supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, 
N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. Additional support was provided by a 
VicHealth Research Fellowship (Dr Peeters) and the National Heart Foundation, Australia (Dr Wong).
Additional Contributions: We thank the staff and participants in the Atherosclerosis Risk in Communities Study 
for their important contributions.
References
1. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related 
maculopathy: a review. Eur J Epidemiol. 2003; 18(9):845–854. [PubMed: 14561043] 
2. Cheung N, Liao D, Islam FM, Klein R, Wang JJ, Wong TY. Is early age-related macular 
degeneration related to carotid artery stiffness? the Atherosclerosis Risk in Communities Study. Br J 
Ophthalmol. 2007; 91(4):430–433. [PubMed: 17035267] 
3. Wong TY, Mitchell P. The eye in hypertension. Lancet. 2007; 369(9559):425–435. [published 
correction appears in Lancet. 2007;369(9579):2078]. [PubMed: 17276782] 
4. Wong TY, Klein R, Sun C, et al. Atherosclerosis Risk in Communities Study. Age-related macular 
degeneration and risk for stroke. Ann Intern Med. 2006; 145(2):98–106. [PubMed: 16847292] 
5. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk 
factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol. 1998; 
116(5):583–587. [PubMed: 9596493] 
6. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular 
degeneration: a case-control study in the age-related eye disease study: Age-Related Eye Disease 
Study Report number 3. Ophthalmology. 2000; 107(12):2224–2232. [PubMed: 11097601] 
7. Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, Vernet MH, POLA Study Group. 
Associations of cardiovascular disease and its risk factors with age-related macular degeneration: 
the POLA study. Ophthalmic Epidemiol. 2001; 8(4):237–249. [PubMed: 11471092] 
8. Klein R, Klein BE, Jensen SC. The relation of cardiovascular disease and its risk factors to the 5-
year incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997; 
104(11):1804–1812. [PubMed: 9373110] 
9. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with 
the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 
2003; 110(4):636–643. [corrected and republished in Ophthalmology. 2003;110(6):1273-1280]. 
[PubMed: 12689879] 
10. Klein BE, Klein R, Lee KE, Jensen SC. Measures of obesity and age-related eye diseases. 
Ophthalmic Epidemiol. 2001; 8(4):251–262. [PubMed: 11471093] 
11. Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index and the incidence of 
visually significant age-related maculopathy in men. Arch Ophthalmol. 2001; 119(9):1259–1265. 
[PubMed: 11545630] 
12. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: 
association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol. 
2003; 121(6):785–792. [PubMed: 12796248] 
13. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular 
degeneration: pooled findings from 3 continents. Ophthalmology. 2004; 111(7):1280–1287. 
[PubMed: 15234127] 
14. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL III. Age-Related Eye Disease Study 
Research Group. Risk factors for the incidence of advanced age-related macular degeneration in 
the Age-Related Eye Disease Study (AREDS): AREDS report No. 19. Ophthalmology. 2005; 
112(4):533–539. [PubMed: 15808240] 
Peeters et al. Page 8













15. Paunksnis A, Cimbalas A, Cerniauskiene LR, et al. Early age-related maculopathy and risk factors 
of cardiovascular disease in middle-aged Lithuanian urban population. Eur J Ophthalmol. 2005; 
15(2):255–262. [PubMed: 15812769] 
16. Moeini HA, Masoudpour H, Ghanbari H. A study of the relation between body mass index and the 
incidence of age related macular degeneration. Br J Ophthalmol. 2005; 89(8):964–966. [PubMed: 
16024844] 
17. Welborn TA, Dhaliwal SS, Bennett SA. Waist-hip ratio is the dominant risk factor predicting 
cardiovascular death in Australia. Med J Aust. 2003; 179(11–12):580–585. [PubMed: 14636121] 
18. ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and 
objectives. Am J Epidemiol. 1989; 129(4):687–702. [PubMed: 2646917] 
19. Hubbard LD, Brothers RJ, King WN, et al. Methods for evaluation of retinal microvascular 
abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities 
Study. Ophthalmology. 1999; 106(12):2269–2280. [PubMed: 10599656] 
20. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-related macular degeneration 
and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. 
Ophthalmology. 2007; 114(1):86–91. [PubMed: 17198851] 
21. Stevens J, Truesdale KP, McClain JE, Cai J. The definition of weight maintenance. Int J Obes 
(Lond). 2006; 30(3):391–399. [PubMed: 16302013] 
22. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Geneva, 
Switzerland: World Health Organization; 1997. 
23. Klein R, Clegg L, Cooper LS, et al. Prevalence of age-related maculopathy in the Atherosclerosis 
Risk in Communities Study. Arch Ophthalmol. 1999; 117(9):1203–1210. [PubMed: 10496392] 
24. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related 
maculopathy grading system. Ophthalmology. 1991; 98(7):1128–1134. [PubMed: 1843453] 
25. National Heart, Lung, and Blood Institute. Atherosclerosis Risk in Communities Study: Operations 
Manual No. 2: Cohort Component Procedures, Version 2.0. Chapel Hill: ARIC Coordinating 
Center, School of Public Health, University of North Carolina; 1988. 
26. Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M, Heiss G. Fibrinogen, other 
putative markers of inflammation, and weight gain in middle-aged adults: the ARIC study. Obes 
Res. 2000; 8(4):279–286. [PubMed: 10933303] 
27. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical 
activity in epidemiological studies. Am J Clin Nutr. 1982; 36(5):936–942. [PubMed: 7137077] 
28. Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in 
African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000; 
283(17):2253–2259. [PubMed: 10807384] 
29. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch 
Ophthalmol. 2004; 122(4):598–614. [PubMed: 15078679] 
30. Kopitz J, Holz FG, Kaemmerer E, Schutt F. Lipids and lipid peroxidation products in the 
pathogenesis of age-related macular degeneration. Biochimie. 2004; 86(11):825–831. [PubMed: 
15589692] 
31. Roth F, Bindewald A, Holz FG. Key pathophysiologic pathways in age-related macular disease. 
Graefes Arch Clin Exp Ophthalmol. 2004; 242(8):710–716. [PubMed: 15309554] 
32. Knudtson MD, Klein R, Klein BE. Physical activity and the 15-year cumulative incidence of age-
related macular degeneration: the Beaver Dam Eye Study. Br J Ophthalmol. 2006; 90(12):1461–
1463. [PubMed: 17077116] 
33. Wannamethee SG, Shaper AG. Weight change and duration of overweight and obesity in the 
incidence of type 2 diabetes. Diabetes Care. 1999; 22(8):1266–1272. [PubMed: 10480769] 
34. Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle 
aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health. 2005; 
59(2):134–139. [PubMed: 15650145] 
35. Wannamethee SG, Shaper AG, Lennon L. Reasons for intentional weight loss, unintentional weight 
loss, and mortality in older men. Arch Intern Med. 2005; 165(9):1035–1040. [PubMed: 15883243] 
Peeters et al. Page 9













36. Stevens VJ, Obarzanek E, Cook NR, et al. Trials for the Hypertension Prevention Research Group. 
Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension 
Prevention, phase II. Ann Intern Med. 2001; 134(1):1–11. [PubMed: 11187414] 
Peeters et al. Page 10














Distribution of percentage change in waist-hip ratio between baseline and the third 
examination for men (A) and women (B).
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Table 2
Baseline Characteristics of Participants With Decreased, Increased, or Stable Waist-Hip Ratio Over 6 Years








Age, mean (SD), yc 54.9 (5.8) 54.0 (5.7) 53.4 (5.8)
Male, % 44.5 44.5 44.5
African American, %c 21.9 21.7 28.6
High school education, %c 77.2 80.4 80.4
Current smoker, % 19.2 17.4 18.8
Prevalent coronary heart disease, % 5.1 4.0 3.9
Prevalent diabetes, %c 19.6 15.0 11.8
Serum glucose level, mean (SD), mg/dLc 110.7 (41.8) 106.1 (33.2) 102.7 (31.5)
Systolic blood pressure, mean (SD), mm Hgc 122.1 (18.7) 119.8 (17.6) 118.4 (16.7)
Diastolic blood pressure, mean (SD), mm Hg 73.4 (11.3) 73.3 (10.7) 73.0 (10.6)
Total cholesterol level, mean (SD), mg/dLc 216.8 (40.6) 215.1 (41.3) 209.5 (40.0)
Triglycerides level, mean (SD), mg/dLc 141.7 (104.4) 131.1 (86.6) 113.0 (68.4)
Fibrinogen level, mean (SD), mg/dLc 306.0 (65.7) 298.5 (61.8) 294.0 (62.1)
White blood cell count, mean (SD), cells/µLc 6.2 (2.1) 6.0 (1.8) 6.1 (2.0)
WHR, mean (SD)c 0.97 (0.08) 0.93 (0.07) 0.86 (0.08)
Obesity, %c,d 33.1 26.5 18.9
Percentage WHR change, mean (SD)c −6.6 (3.7) 1.9 (3.2) 11.8 (7.0)
Abbreviation: WHR, waist-hip ratio.
SI conversion factors: To convert glucose to millimoles per liter, multiply by 0.0555. To convert total cholesterol to millimoles per liter, multiply by 
0.0259. To convert triglycerides to millimoles per liter, multiply by 0.0113. To convert fibrinogen to micromoles per liter, multiply by 0.0294. To 
convert white blood cell count to ×109/L, multiply by 0.001.
a
From baseline to the third examination.
b
Decrease and increase in WHR are defined as the bottom and top sex-specific deciles, respectively, of percentage change in WHR over the 6-year 
follow-up.
c
Indicates significant differences between categories by analysis of variance, P<.05.
d
Indicates body mass index (calculated as weight in kilograms divided by height in meters squared) of 30 or higher.
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Table 3
Cross-sectional Association of Waist-Hip Ratio and Age-Related Macular Degeneration at the Third 
Examination
OR (95% CI) of AMD, Per 1-SD Change






Adjusted for Age, Sex,
Race, and Centera Multivariate-Adjustedb
Any AMD 608 12 506 1.09 (1.00–1.20) 1.14 (1.02–1.27)
Early AMD 591 12 506 1.08 (0.99–1.19) 1.11 (1.00–1.24)
Late AMD 17 12 506 1.37 (1.00–1.90) 1.36 (1.02–1.83)
Soft drusen 504 12 506 1.07 (0.96–1.18) 1.09 (0.96–1.22)
RPE abnormalities 293 12 506 1.14 (1.01–1.30) 1.20 (1.04–1.39)
Abbreviations: AMD, age-related macular degeneration; CI, confidence interval; OR, odds ratio; RPE, retinal pigment epithelium; WHR, waist-hip 
ratio.
a
Adjusted in logistic regression models.
b
Adjusted additionally for body mass index (calculated as weight in kilograms divided by height in meters squared), smoking status, years of 
cigarette smoking, systolic blood pressure, prior coronary heart disease, diabetes, total cholesterol level, high-density lipoprotein cholesterol level, 
and serum glucose level measured at examination 3 and fibrinogen level, white blood cell count, and physical activity level measured at baseline.
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